Treatment with atorvastatin reduces serum adipocyte‐fatty acid binding protein value in patients with hyperlipidaemia

Karpíšek, Michal; Stejskal, David; Kotolová, Hana; Kollár, Péter; Janoutová, Gabriela; Ochmanova, Radka; Čížek, Luděk; Horáková, D; Yahia, Rabha Ben; Lichnovská, Radka; Janout, Vladimí­r

doi:10.1111/j.1365-2362.2007.01835.x

Cited by 65 publications

(46 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For people with pre-existing coronary heart disease, a significantly higher concentration of AFABP4 predicted increased risk of cardiovascular death, nonfatal myocardial infarction or stroke 48 . Expression of the adipocyte fatty-acid-binding protein (FABP4) gene in macrophages can be induced by oxidized LDL cholesterol and decreased by administration of lipid-lowering drugs (statins), which inhibit cholesterol synthesis 49 . Treatment of patients with obstructive sleep apnea using CPAP favorably affects AFABP levels 50 .…”

Section: Adipocyte Fatty-acid-binding Protein (A-fabp)mentioning

confidence: 99%

Adipokines and cardiovascular disease: A comprehensive review

Smékal¹,

Václavík²

2017

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

Section: Adipocyte Fatty-acid-binding Protein (A-fabp)mentioning

confidence: 99%

Adipokines and cardiovascular disease: A comprehensive review

Smékal¹,

Václavík²

2017

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

“…10 ), which was not confirmed by CRP measurements in Group C. Group C subjects have already been treated for metabolic syndrome, most of them with atorvastatin. Statins are known to lower both CRP and aFABP levels 11 . In untreated individuals, the levels of both parameters could be even higher.…”

Section: Discussionmentioning

confidence: 99%

Adipocyte Fatty Acid Binding Protein and C-Reactive Protein Levels as Indicators of Insulin Resistance Development

Horáková

Pastucha²,

Stejskal³

et al. 2011

BIOMED PAP

View full text Add to dashboard Cite

Background. Adipocyte fatty acid-binding protein (aFABP) has recently been identified as a potential circulating marker for metabolic syndrome. C-reactive protein (CRP), a sensitive marker of inflammation, is increased in individuals with diabetes and metabolic syndrome due to the development of subclinical inflammation. The study uses logistic regression models to analyze the relations between aFABP and CRP along with other parameters of insulin resistance. The objective was to investigate the potential use of aFABP and CRP levels as tools in the diagnosis of the metabolic syndrome.Methods and results. The following groups were studied: healthy individuals (A, n=122), obese ind1ividuals (B, n=213) and patients diagnosed with metabolic syndrome (C, n=79). Obese persons in Group B had parameters suggestive of early insulin resistance: hypertension, hyperglycaemia, QUICKI (0.305) and higher aFABP levels as compared with the healthy subjects. Group C individuals were diagnosed with metabolic syndrome, as evidenced by the QUICKI markers for insulin resistance (0.293), high aFABP levels (35.3 mg/l). CRP concentrations were lowest in Group A healthy individuals (0.67 mg/l), higher in Group B obese subjects (2.65 mg/l) and highest in Group C patients with metabolic syndrome (3.62 mg/l). Logistic regression models showed an association of aFABP and CRP with BMI (OR 1.12 and 1.39, compared Group A vs C). An association of aFABP and CRP with the QUICKI index showed OR 1.48 and 1.37 (Group A vs C); with triglyceride levels showed OR 1.68 and 1.52 (Group A vs C). An association of aFABP and CRP with glycaemia showed OR 1.48 and 1.51 (Group A vs C), with insulinaemia showed OR 1.44 and 1.38 (Group A vs C) respectively.Conclusions. AFABP levels were higher in obese individuals and highest in those with metabolic syndrome. CRP concentrations were increased in obese persons whereas individuals with metabolic syndrome were found to have high-risk CRP levels. Logistic regression models showed an association of aFABP and CRP with BMI as well as an association of aFABP and CRP with parameters of insulin resistance, namely the QUICKI index, triglyceride levels, glycaemia and insulinaemia. Both methods are of diagnostic benefit for predicting metabolic syndrome, especially in previously untreated patients.

show abstract

“…Furthermore, elevation of the circulating FABP4 level is associated with obesity, insulin resistance, hypertension, cardiac dysfunction, dyslipidemia, and atherosclerosis 15, 16, 17, 18, 19, 20, 21. Several drugs for dyslipidemia, diabetes mellitus, and hypertension have been reported to modulate FABP4 levels 22, 23, 24, 25, 26, 27, 28…”

Section: Introductionmentioning

confidence: 99%

Ectopic Fatty Acid–Binding Protein 4 Expression in the Vascular Endothelium is Involved in Neointima Formation After Vascular Injury

Fuseya

Furuhashi

Matsumoto

et al. 2017

JAHA

View full text Add to dashboard Cite

BackgroundFatty acid‐binding protein 4 (FABP4) is expressed in adipocytes, macrophages, and endothelial cells of capillaries but not arteries. FABP4 is secreted from adipocytes in association with lipolysis, and an elevated circulating FABP4 level is associated with obesity, insulin resistance, and atherosclerosis. However, little is known about the link between FABP4 and endovascular injury. We investigated the involvement of ectopic FABP4 expression in endothelial cells in neointima hyperplasia after vascular injury.Methods and ResultsFemoral arteries of 8‐week‐old male mice were subjected to wire‐induced vascular injury. After 4 weeks, immunofluorescence staining showed that FABP4 was ectopically expressed in endothelial cells of the hyperplastic neointima. Neointima formation determined by intima area and intima to media ratio was significantly decreased in FABP4‐defficient mice compared with that in wild‐type mice. Adenovirus‐mediated overexpression of FABP4 in human coronary artery endothelial cells (HCAECs) in vitro increased inflammatory cytokines and decreased phosphorylation of nitric oxide synthase 3. Furthermore, FABP4 was secreted from HCAECs. Treatment of human coronary smooth muscle cells or HCAECs with the conditioned medium of Fabp4‐overexpressed HCAECs or recombinant FABP4 significantly increased gene expression of inflammatory cytokines and proliferation‐ and adhesion‐related molecules in cells, promoted cell proliferation and migration of human coronary smooth muscle cells, and decreased phosphorylation of nitric oxide synthase 3 in HCAECs, which were attenuated in the presence of an anti‐FABP4 antibody.ConclusionsEctopic expression and secretion of FABP4 in vascular endothelial cells contribute to neointima formation after vascular injury. Suppression of ectopic FABP4 in the vascular endothelium would be a novel strategy against post‐angioplasty vascular restenosis.

show abstract

Treatment with atorvastatin reduces serum adipocyte‐fatty acid binding protein value in patients with hyperlipidaemia

Abstract: In conclusion, our study confirmed in vivo that atorvastatin reduces serum A-FABP by a pleiotropic mechanism and supports the hypothesis that A-FABP is involved in atherosclerotic actions.

Cited by 65 publications

References 31 publications

Adipokines and cardiovascular disease: A comprehensive review

Adipokines and cardiovascular disease: A comprehensive review

Adipocyte Fatty Acid Binding Protein and C-Reactive Protein Levels as Indicators of Insulin Resistance Development

Ectopic Fatty Acid–Binding Protein 4 Expression in the Vascular Endothelium is Involved in Neointima Formation After Vascular Injury

Contact Info

Product

Resources

About